NFKB1 and breast carcinoma: Bcl3 has been implicated with a role in tumour progression and is activated alongside NF-κB subunits p50 and p52 in breast cancer [19]; however, Bcl3 knockout mice remain viable with minimal adverse effects and show increased apoptosis in mammary glands, making it an attractive therapeutic target [20,21].